ORGO
Q4 2026 EPS Estimate
$-0.18
Nov 5, 2026
Revenue Estimate
$52M

Analyst Sentiment

Wall St. Consensus
Buy
6 analysts·Limited coverage
67
Score
4 Buy (67%)2 Hold (33%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
467%
Hold
233%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
+11.1%
Consensus
$2.50
+38.9%
Bull
$3.00
+66.7%
12-Month Target Range6 analysts
$2.00$2.50$3.00
Current $1.80Consensus
Current Price
$1.80
Upside to Consensus
$0.70

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+37.56%
EPS
FY2028
Rev+11.61%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$196M$270M$301M
Low$192M$240M$258M
High$201M$299M$344M
EBITDA Avg$20M$28M$31M
Low$20M$25M$27M
High$21M$31M$36M
EBIT Avg$12M$17M$19M
Low$12M$15M$16M
High$12M$19M$21M
Net Income Avg$-170M$-34M$-26M
Low$-200M$-51M$-32M
High$-158M$-30M$-21M
EPS Avg$-1.38$-0.31$-0.20
Low$-1.54$-0.39$-0.24
High$-1.22$-0.23$-0.16
Analysts (Rev / EPS)2 / 12 / 22 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$52M$63M$54M$62M$73M$99M$56M$62M
Low$52M$63M$54M$61M$73M$98M$56M$62M
High$53M$63M$55M$62M$73M$99M$56M$62M
EBITDA Avg$5M$7M$6M$6M$8M$10M$6M$6M
Low$5M$7M$6M$6M$8M$10M$6M$6M
High$5M$7M$6M$6M$8M$10M$6M$6M
EBIT Avg$3M$4M$3M$4M$5M$6M$3M$4M
Low$3M$4M$3M$4M$5M$6M$3M$4M
High$3M$4M$3M$4M$5M$6M$3M$4M
Net Income Avg$-23M$-18M$-10M$-8M$-7M$-5M$-6M$-5M
Low$-23M$-21M$-10M$-8M$-7M$-5M$-6M$-6M
High$-23M$-14M$-10M$-8M$-7M$-5M$-6M$-5M
EPS Avg$-0.18$-0.14$-0.08$-0.06$-0.06$-0.04$-0.05$-0.04
Low$-0.18$-0.16$-0.08$-0.06$-0.06$-0.04$-0.05$-0.04
High$-0.18$-0.11$-0.08$-0.06$-0.06$-0.04$-0.05$-0.04
Analysts (Rev / EPS)2 / 11 / 21 / 11 / 11 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026Truist Financial
Organogenesis price target lowered to $2 from $3 at Truist
Target:$2.00
+22.0%from $1.64
May 28, 2026UBS
Organogenesis initiated with a Hold at Truist
Target:$3.00
+12.8%from $2.66
May 28, 2026Truist Financial
Truist Securities Starts Oranogenesis Holdings (ORGO) at Hold
Target:$3.00
+12.8%from $2.66
Nov 20, 2025BTIG
Organogenesis price target raised to $9 from $7 at BTIG
Target:$9.00
+75.1%from $5.14
Mar 5, 2025Morgan Stanley
Organogenesis price target raised to $6 from $4 at Morgan Stanley
Target:$6.00
-0.2%from $6.01
Jun 28, 2024Lake Street
Organogenesis initiated with a Buy at Lake Street
Target:$5.00
+89.4%from $2.64
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.